D
David F. Paulson
Researcher at Duke University
Publications - 247
Citations - 11606
David F. Paulson is an academic researcher from Duke University. The author has contributed to research in topics: Prostatectomy & Prostate. The author has an hindex of 54, co-authored 247 publications receiving 11439 citations. Previous affiliations of David F. Paulson include National Institutes of Health & Baylor College of Medicine.
Papers
More filters
Journal ArticleDOI
Isolation of a human prostate carcinoma cell line (DU 145).
TL;DR: Electron microscopy of the original tumor tissue and of the tissue culture cell line show a remarkable similarity in cell organelle structure.
Journal ArticleDOI
Genetic Risk and Carcinogen Exposure: a Common Inherited Defect of the Carcinogen-Metabolism Gene Glutathione S-Transferase M1 (GSTM1) That Increases Susceptibility to Bladder Cancer
Douglas A. Bell,Jack A. Taylor,David F. Paulson,Cary N. Robertson,James L. Mohler,George W. Lucier +5 more
TL;DR: These findings support a protective role for the GSTM1 gene in bladder cancer and suggest that 25% of all bladder cancer may be attributable to the at-risk GSTM 1 0/0 genotype.
Journal ArticleDOI
Surgical management and prognosis of renal cell carcinoma invading the vena cava.
TL;DR: Patients with incomplete resection of localized renal cell carcinoma with tumor thrombus do not survive any longer than those with extensive cancer, positive lymph nodes or distant metastases, however, when partial venacavectomy establishes negative surgical margins then survival markedly improves.
Journal ArticleDOI
Radical surgery versus radiotherapy for adenocarcinoma of the prostate
TL;DR: With time to first evidence of treatment failure used as the end point for determination of treatment efficacy, radical prostatectomy was shown to be more effective than megavoltage radiation in establishing disease control.
Journal ArticleDOI
Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer.
Stephen D. Williams,Stablein Dm,Lawrence H. Einhorn,Muggia Fm,Weiss Rb,John P. Donohue,David F. Paulson,K.W. Brunner,E.M. Jacobs,Spaulding Jt +9 more
TL;DR: Two courses of cisplatin-based adjuvant chemotherapy will almost always prevent relapse in pathological Stage II testicular cancer treated with orchiectomy and retroperitoneal-lymph-node dissection, however, when surgery, follow-up, and chemotherapy are optimal, observation with chemotherapy only for relapse will lead to equivalent cure rates.